Literature DB >> 11707055

QT prolongation associated with azithromycin/amiodarone combination.

P Samarendra1, S Kumari, S J Evans, T J Sacchi, V Navarro.   

Abstract

Administration of oral azithromycin, in addition to previously well-tolerated long-term amiodarone therapy, was associated with a marked prolongation of QT interval and increased QT dispersion, both substrates for life-threatening ventricular tachyarrhythmia and torsades de pointes. This is a report of QT prolongation and increased QT dispersion associated with the use of azithromycin. The report assumes an added significance, in view of widespread empirical use of this antibiotic for the treatment of lower respiratory infections and belief of its safety in patients with cardiac diseases. Based on the authors' experience, they would like to emphasize that the combination of azithromycin with other drugs known to prolong QT or causing torsades de pointes be used with caution until the question of the proarrhythmic effect of azithromycin is resolved by further studies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11707055     DOI: 10.1046/j.1460-9592.2001.01572.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  27 in total

1.  Azithromycin and the risk of cardiovascular death.

Authors:  Wayne A Ray; Katherine T Murray; Kathi Hall; Patrick G Arbogast; C Michael Stein
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

2.  Azithromycin Causes a Novel Proarrhythmic Syndrome.

Authors:  Zhenjiang Yang; Joseph K Prinsen; Kevin R Bersell; Wangzhen Shen; Liudmila Yermalitskaya; Tatiana Sidorova; Paula B Luis; Lynn Hall; Wei Zhang; Liping Du; Ginger Milne; Patrick Tucker; Alfred L George; Courtney M Campbell; Robert A Pickett; Christian M Shaffer; Nagesh Chopra; Tao Yang; Bjorn C Knollmann; Dan M Roden; Katherine T Murray
Journal:  Circ Arrhythm Electrophysiol       Date:  2017-04

3.  Should azithromycin no longer be considered a drug of choice for community-acquired pneumonia because of its potential to cause cardiovascular death?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2013-09

4.  Macrolide antibiotics and the risk of ventricular arrhythmia in older adults.

Authors:  Mai H Trac; Eric McArthur; Racquel Jandoc; Stephanie N Dixon; Danielle M Nash; Daniel G Hackam; Amit X Garg
Journal:  CMAJ       Date:  2016-02-22       Impact factor: 8.262

5.  Giant inverted T waves and substantial QT interval prolongation induced by azithromycin in an elderly woman with renal insufficiency.

Authors:  Tongtong Yu; Tiesheng Niu
Journal:  Can Fam Physician       Date:  2014-11       Impact factor: 3.275

6.  Use of azithromycin and risk of ventricular arrhythmia.

Authors:  Gianluca Trifirò; Maria de Ridder; Janet Sultana; Alessandro Oteri; Peter Rijnbeek; Serena Pecchioli; Giampiero Mazzaglia; Irene Bezemer; Edeltraut Garbe; Tania Schink; Elisabetta Poluzzi; Trine Frøslev; Mariam Molokhia; Igor Diemberger; Miriam C J M Sturkenboom
Journal:  CMAJ       Date:  2017-04-18       Impact factor: 8.262

7.  Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death.

Authors:  Gowtham A Rao; Joshua R Mann; Azza Shoaibi; Charles Lee Bennett; Georges Nahhas; S Scott Sutton; Sony Jacob; Scott M Strayer
Journal:  Ann Fam Med       Date:  2014 Mar-Apr       Impact factor: 5.166

8.  Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People.

Authors:  C Franchi; I Ardoino; R Rossio; A Nobili; E M Biganzoli; A Marengoni; M Marcucci; L Pasina; M Tettamanti; S Corrao; P M Mannucci
Journal:  Drugs Aging       Date:  2016-01       Impact factor: 3.923

Review 9.  Cardiac risks associated with antibiotics: azithromycin and levofloxacin.

Authors:  Zhiqiang Kevin Lu; Jing Yuan; Minghui Li; S Scott Sutton; Gowtham A Rao; Sony Jacob; Charles L Bennett
Journal:  Expert Opin Drug Saf       Date:  2014-12-10       Impact factor: 4.250

Review 10.  QT prolongation with antimicrobial agents: understanding the significance.

Authors:  Robert C Owens
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.